Swiss-German radiopharmaceutical developer Nuclidium secured $98 million in Series B funding to propel clinical development and expand production of its copper-based radiotheranostics. The firm’s platform pairs diagnostic Copper-61 with therapeutic Copper-67 isotopes, aiming to outperform current standards in oncology treatment. Investors include strategic growth funds and venture capitalists with expertise in deeptech and climate sectors. Nuclidium’s approach integrates seamlessly into hospital workflows and addresses persistent production and effectiveness challenges in the radiotheranostics field.